Click on the dots on the map to find out more about the different trial centres in DevelopAKUre.
The Royal Liverpool University Hospital is home to the National AKU Centre and some of the world’s leading experts on the disease.
The Hôpital Necker, France, houses a national metabolic centre that treats several AKU patients and uses nitisinone for tyrosinaemia patients.
The National Institute of Rheumatic Disease, Slovakia, has been studying AKU for 60 years, and cares for the world’s largest community of AKU patients.
DevelopAKUre is a series of major international clinical trials, run by a consortium of 12 European partners. It aims to study a potential new drug, called nitisinone, and assess its potential effectiveness in treating the rare disease, alkaptonuria (AKU).
DevelopAKUre is co-funded by a grant from the European Commission. This website is run by a UK patient group, the AKU Society. Learn more about AKU on the AKU Society's What is AKU page.
In today’s blog Chief investigator Prof. Ranganath reinforces the need for SONIA 2 pat.. ...more